Previous Close | 0.26 |
Open | 0.26 |
Bid | 0.20 x 600 |
Ask | 0.33 x 500 |
Day's Range | 0.26 - 0.28 |
52 Week Range | 0.25 - 3.34 |
Volume | 396,410 |
Avg. Volume | 1,590,161 |
Market Cap | 6.329M |
Beta | 0.69 |
PE Ratio (TTM) | 10.00 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, ...
FDA Confirms Vitaros Regulatory Pathway. Company Seeking Partner to Develop Vitaros in U.S.. SAN DIEGO, April 16, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines ...
SAN DIEGO, April 04, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the closing of its previously announced public ...
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...
SAN DIEGO, March 28, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has priced a public offering of an ...
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...
SAN DIEGO, March 27, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of ...
Meeting Scheduled for April 12, 2018 SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, ...
SAN DIEGO, March 26, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review meeting with the U.S. ...
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
Stock Monitor: Apricus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Cardiome Pharma Corp. (NASDAQ: CRME ...
Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call / Webcast ...
Company Expects to Submit Vitaros End of Review Meeting Request This Month. Vitaros End-of-Review Meeting Expected to Occur in April 2018. Company Expects Cash Runway Through 2018.
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Apricus Biosciences, Inc. (NASDAQ: APRI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018, at 4:30 PM Eastern ...
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company`s ...
SAN DIEGO, Feb. 21, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full ...
Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines ...
SAN DIEGO, Feb. 16, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ...
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus` ...
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard ...
NEW YORK, NY / ACCESSWIRE / October 3, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has ...